ArticleThe Journal of pathology2013
UTRly malignant: mRNA stability and the invasive phenotype in breast cancer.
Article in The Journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Regulation of the mRNA half-life in breast cancer.World journal of clinical oncology · 2014Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Alterations in gene expression are central to the malignant phenotype. In this issue, Al-Ahmadi et al elegantly demonstrate that one key mechanism that determines invasiness in breast cancer is likely to be dysregulation of mRNA stability. This is achieved by altered expression of the proteins TTP and HuR, which bind 3' untranslated region (UTR) elements in cancer-related genes. The authors link this to the expression of a miRNA, miR-29a, and show that anti-miR-29a treatment can reverse the invasive phenotype in vitro. This further highlights the important roles of mRNA UTRs in malignant transformation, and the importance of investigating post-transcriptional disease mechanisms. Such mechanisms have the potential to provide novel therapeutic targets, as well as being vital to further our understanding of cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.